Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

Gautam Borthakur, Hagop Kantarjian, George Daley, Moshe Talpaz, Susan O'Brien, Guillermo Garcia-Manero, Francis Giles, Stefan Faderl, Mary Sugrue, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Lonafarnib (SCH66336) is a nonpeptidomimetic farnesyl transferase inhibitor that has demonstrated significant preclinical activity against chronic myelogenous leukemia (CML) cells and in CML animal models. METHODS. In the current study, the efficacy of lonafarnib was investigated in patients with CML in the chronic or accelerated phase that was resistant or intolerant to imatinib. Thirteen patients with CML in the chronic (n = 6 patients) or accelerated (n = 7 patients) phase were treated with lonafarnib at a dose of 200 mg orally twice daily. Ten patients had failed therapy with imatinib and 3 patients were intolerant to imatinib. The median age of the patients was 62 years (range, 38-80 yrs) and the median time from the diagnosis of CML to therapy with lonafarnib was 5 years (range, 0.3-13 yrs). In addition to imatinib mesylate, all patients had received prior therapy with interferon-α and seven patients had received other treatments. The median duration of therapy with lonafarnib was 8 weeks (range, 2-41 wks). RESULTS. Two patients responded. One patient in the accelerated phase of CML returned to the chronic phase, a response that lasted for 3 months. Another patient with chronic phase disease had lowering of the leukocyte count without the need for hydroxyurea and normalization of the differential count that lasted for 5 months. The most common adverse event was diarrhea, which was noted in 11 patients (84%) (Grade ≥ 3 in 4 patients; 31%; toxicity was graded according to the National Cancer Institute Common Toxicity Criteria [version 2.0]). Therapy was discontinued in one patient because of diarrhea not responding to dose adjustments. CONCLUSIONS. Single-agent lonafarnib appears to have clinical activity in a small proportion of patients with CML refractory to imatinib.

Original languageEnglish (US)
Pages (from-to)346-352
Number of pages7
JournalCancer
Volume106
Issue number2
DOIs
StatePublished - Jan 15 2006
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Transferases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Imatinib Mesylate
lonafarnib
Diarrhea
Hydroxyurea
National Cancer Institute (U.S.)

Keywords

  • Accelerated phase
  • Chronic myeloid leukemia (CML)
  • Chronic phase
  • Farnesyl transferase inhibitor
  • Ionafarnib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. / Borthakur, Gautam; Kantarjian, Hagop; Daley, George; Talpaz, Moshe; O'Brien, Susan; Garcia-Manero, Guillermo; Giles, Francis; Faderl, Stefan; Sugrue, Mary; Cortes, Jorge.

In: Cancer, Vol. 106, No. 2, 15.01.2006, p. 346-352.

Research output: Contribution to journalArticle

Borthakur, Gautam ; Kantarjian, Hagop ; Daley, George ; Talpaz, Moshe ; O'Brien, Susan ; Garcia-Manero, Guillermo ; Giles, Francis ; Faderl, Stefan ; Sugrue, Mary ; Cortes, Jorge. / Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. In: Cancer. 2006 ; Vol. 106, No. 2. pp. 346-352.
@article{15478cb9f6464a18af257c03e0d4b7d3,
title = "Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy",
abstract = "BACKGROUND. Lonafarnib (SCH66336) is a nonpeptidomimetic farnesyl transferase inhibitor that has demonstrated significant preclinical activity against chronic myelogenous leukemia (CML) cells and in CML animal models. METHODS. In the current study, the efficacy of lonafarnib was investigated in patients with CML in the chronic or accelerated phase that was resistant or intolerant to imatinib. Thirteen patients with CML in the chronic (n = 6 patients) or accelerated (n = 7 patients) phase were treated with lonafarnib at a dose of 200 mg orally twice daily. Ten patients had failed therapy with imatinib and 3 patients were intolerant to imatinib. The median age of the patients was 62 years (range, 38-80 yrs) and the median time from the diagnosis of CML to therapy with lonafarnib was 5 years (range, 0.3-13 yrs). In addition to imatinib mesylate, all patients had received prior therapy with interferon-α and seven patients had received other treatments. The median duration of therapy with lonafarnib was 8 weeks (range, 2-41 wks). RESULTS. Two patients responded. One patient in the accelerated phase of CML returned to the chronic phase, a response that lasted for 3 months. Another patient with chronic phase disease had lowering of the leukocyte count without the need for hydroxyurea and normalization of the differential count that lasted for 5 months. The most common adverse event was diarrhea, which was noted in 11 patients (84{\%}) (Grade ≥ 3 in 4 patients; 31{\%}; toxicity was graded according to the National Cancer Institute Common Toxicity Criteria [version 2.0]). Therapy was discontinued in one patient because of diarrhea not responding to dose adjustments. CONCLUSIONS. Single-agent lonafarnib appears to have clinical activity in a small proportion of patients with CML refractory to imatinib.",
keywords = "Accelerated phase, Chronic myeloid leukemia (CML), Chronic phase, Farnesyl transferase inhibitor, Ionafarnib",
author = "Gautam Borthakur and Hagop Kantarjian and George Daley and Moshe Talpaz and Susan O'Brien and Guillermo Garcia-Manero and Francis Giles and Stefan Faderl and Mary Sugrue and Jorge Cortes",
year = "2006",
month = "1",
day = "15",
doi = "10.1002/cncr.21590",
language = "English (US)",
volume = "106",
pages = "346--352",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

AU - Borthakur, Gautam

AU - Kantarjian, Hagop

AU - Daley, George

AU - Talpaz, Moshe

AU - O'Brien, Susan

AU - Garcia-Manero, Guillermo

AU - Giles, Francis

AU - Faderl, Stefan

AU - Sugrue, Mary

AU - Cortes, Jorge

PY - 2006/1/15

Y1 - 2006/1/15

N2 - BACKGROUND. Lonafarnib (SCH66336) is a nonpeptidomimetic farnesyl transferase inhibitor that has demonstrated significant preclinical activity against chronic myelogenous leukemia (CML) cells and in CML animal models. METHODS. In the current study, the efficacy of lonafarnib was investigated in patients with CML in the chronic or accelerated phase that was resistant or intolerant to imatinib. Thirteen patients with CML in the chronic (n = 6 patients) or accelerated (n = 7 patients) phase were treated with lonafarnib at a dose of 200 mg orally twice daily. Ten patients had failed therapy with imatinib and 3 patients were intolerant to imatinib. The median age of the patients was 62 years (range, 38-80 yrs) and the median time from the diagnosis of CML to therapy with lonafarnib was 5 years (range, 0.3-13 yrs). In addition to imatinib mesylate, all patients had received prior therapy with interferon-α and seven patients had received other treatments. The median duration of therapy with lonafarnib was 8 weeks (range, 2-41 wks). RESULTS. Two patients responded. One patient in the accelerated phase of CML returned to the chronic phase, a response that lasted for 3 months. Another patient with chronic phase disease had lowering of the leukocyte count without the need for hydroxyurea and normalization of the differential count that lasted for 5 months. The most common adverse event was diarrhea, which was noted in 11 patients (84%) (Grade ≥ 3 in 4 patients; 31%; toxicity was graded according to the National Cancer Institute Common Toxicity Criteria [version 2.0]). Therapy was discontinued in one patient because of diarrhea not responding to dose adjustments. CONCLUSIONS. Single-agent lonafarnib appears to have clinical activity in a small proportion of patients with CML refractory to imatinib.

AB - BACKGROUND. Lonafarnib (SCH66336) is a nonpeptidomimetic farnesyl transferase inhibitor that has demonstrated significant preclinical activity against chronic myelogenous leukemia (CML) cells and in CML animal models. METHODS. In the current study, the efficacy of lonafarnib was investigated in patients with CML in the chronic or accelerated phase that was resistant or intolerant to imatinib. Thirteen patients with CML in the chronic (n = 6 patients) or accelerated (n = 7 patients) phase were treated with lonafarnib at a dose of 200 mg orally twice daily. Ten patients had failed therapy with imatinib and 3 patients were intolerant to imatinib. The median age of the patients was 62 years (range, 38-80 yrs) and the median time from the diagnosis of CML to therapy with lonafarnib was 5 years (range, 0.3-13 yrs). In addition to imatinib mesylate, all patients had received prior therapy with interferon-α and seven patients had received other treatments. The median duration of therapy with lonafarnib was 8 weeks (range, 2-41 wks). RESULTS. Two patients responded. One patient in the accelerated phase of CML returned to the chronic phase, a response that lasted for 3 months. Another patient with chronic phase disease had lowering of the leukocyte count without the need for hydroxyurea and normalization of the differential count that lasted for 5 months. The most common adverse event was diarrhea, which was noted in 11 patients (84%) (Grade ≥ 3 in 4 patients; 31%; toxicity was graded according to the National Cancer Institute Common Toxicity Criteria [version 2.0]). Therapy was discontinued in one patient because of diarrhea not responding to dose adjustments. CONCLUSIONS. Single-agent lonafarnib appears to have clinical activity in a small proportion of patients with CML refractory to imatinib.

KW - Accelerated phase

KW - Chronic myeloid leukemia (CML)

KW - Chronic phase

KW - Farnesyl transferase inhibitor

KW - Ionafarnib

UR - http://www.scopus.com/inward/record.url?scp=30744446226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30744446226&partnerID=8YFLogxK

U2 - 10.1002/cncr.21590

DO - 10.1002/cncr.21590

M3 - Article

C2 - 16342165

AN - SCOPUS:30744446226

VL - 106

SP - 346

EP - 352

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -